Eflornithine plus sulindac
Asset
Combines inhibition of polyamine synthesis and cyclooxygenases to prevent colorectal adenomas and second primary colorectal cancers.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Colorectal neoplasm
Phase 3, Active not recruiting, NCT01349881, clinicaltrials.gov, Oct 23, 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors9
Every asset’s record: target, stage, trials and the evidence behind it.